Autoimmune Diseases  >>  ELND 002  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ELND 002 / Perrigo Company
NCT01144351: A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Terminated
1b
32
US, Canada
ELND002, Placebo
Elan Pharmaceuticals
Multiple Sclerosis
12/12
 
NCT01318421: A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Terminated
1
12
US
ELND002
Elan Pharmaceuticals
Multiple Sclerosis
12/12
 

Download Options